

nad aktivitou závažného autoimunního onemocnění, kterým SLE bezesporu je. Slibná jsou první data o účinnosti ustekinumabu (inhibice IL-12/23), probíhají klinická hodnocení s dalšími blokátory interferonu 1,

inhibicí kostimulace T buněk či s inhibitory Janusových kináz (baricitinib, filgotinib) a inhibitory proteazomu (bortezomib).

Podpořeno MZ ČR RVO FNOL-0098892 a grantem IGA_LF_2022_003.

LITERATURA

- Horák P, Skácelová M, Schubertová M. Život ohrožující projevy systémového lupusu a antifosfolipidového syndromu ve vnitřním lékařství. *Vnitř Lék* 2018;64(2):136-145.
- Arlinger M, Costenbader K, Daikh D et al. 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. *Arthritis Rheumatol*. 2019 Sep;71(9):1400-1412. doi: 10.1002/art.40930. Epub 2019 Aug 6. PMID: 31385462; PMCID: PMC6827566.
- Fanouriakis A, Kostopoulou M, Alunno A et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. *Annals of the Rheumatic Diseases*. 2019;78:736-745.
- Fanouriakis A, Kostopoulou M, Cheema K et al. 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. *Annals of the Rheumatic Diseases*. 2020;79:713-723.
- Horák P, Tegzová D, Závada J et al. Doporučení ČRS pro léčbu nemocných se SLE. *Čes Revmatol*. 2013;21:110-122.
- Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P et al. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. *Ann Rheum Dis*. 2010;69:20-8. doi:10.1136/ard.2008.101766.
- Yap DYH, Chan TM. What is the ideal duration of maintenance therapy for lupus nephritis? *Expert Rev Clin Immunol*. 2022 Mar 19. doi: 10.1080/1744666X.2022.2056020. Epub ahead of print. PMID: 35306959.
- Sciascia S, Radin M, Yazdany J et al. Efficacy of belimumab on renal outcomes in patients with systemic lupus erythematosus: a systematic review. *Autoimmun Rev* 2017;16:287-93. doi:10.1016/j.autrev.2017.01.010 pmid:http://www.ncbi.nlm.nih.gov/pubmed/28147262.
- Furie R, Rovin BH, Houssiau F et al. Two-year, randomized, controlled trial of belimumab in lupus nephritis. *N Engl J Med*. 2020;383:1117-1128.
- Kraaij T, Kamerling SWA, de Rooij ENM et al. The NET-effect of combining rituximab with belimumab in severe systemic lupus erythematosus. *J Autoimmun* 2018;91:45-54. doi:10.1016/j.jaut.2018.03.003.
- van Gelder T, Huizinga RB, Lisk L, Solomons N. Voclosporin: a novel calcineurin inhibitor with no impact on mycophenolic acid levels in patients with SLE. *Nephrol Dial Transplant*. 2022 Apr 25;37(5):917-922. doi: 10.1093/ndt/gfab022.
- Rovin BH, Solomons N, Pendergraft WF 3rd et al. A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis. *Kidney Int*. 2019;95:219-231.
- Rovin BH, Teng YKO, Ginzler EM, Arriens C et al. Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. *Lancet*. 2021 May 29;397(10289):2070-2080. doi: 10.1016/S0140-6736(21)00578-X. Epub 2021 May 7. Erratum in: *Lancet*. 2021 May 29;397(10289):2048. PMID: 33971155.
- Navarra SV, Guzmán RM, Gallacher AE et al. BLISS-52 Study Group. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. *Lancet*. 2011;377:721-731.
- Furie R, Petri M, Zamani O et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. BLISS-76 Study Group. *Arthritis Rheum*. 2011;63:3918-3930.
- Wallace DJ, Ginzler EM, Merrill JT et al. Safety and Efficacy of Belimumab Plus Standard Therapy for Up to Thirteen Years in Patients With Systemic Lupus Erythematosus. *Arthritis Rheumatol*. 2019 Jul;71(7):1125-1134. doi: 10.1002/art.40861. Epub 2019 Jun 5. PMID: 30771238; PMCID: PMC6617785.
- Iaccarino L, Andreoli L, Bocci EB et al. Clinical predictors of response and discontinuation of belimumab in patients with systemic lupus erythematosus in real life setting. Results of a large, multicentric, nationwide study. *J Autoimmun*. 2018;86:1-8. doi:10.1016/j.jaut.2017.09.004.
- van Vollenhoven RF, Petri MA, Cervera R et al. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. *Ann Rheum Dis*. 2012;71:1343-9. doi:10.1136/annrheumdis-2011-200937.
- Merrill JT, Neuwelt CM, Wallace DJ et al. Efficacy and safety of rituximab in moderately- to severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. *Arthritis Rheum*. 2010 Jan;62(1):222-33. doi: 10.1002/art.27233. PMID: 20039413; PMCID: PMC4548300.
- Rovin BH, Furie R, Latinis K et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. *Arthritis Rheum*. 2012 Apr;64(4):1215-26. doi: 10.1002/art.34359. Epub 2012 Jan 9. PMID: 22231479.
- Gomez Mendez LM, Cascino MD, Garg J et al. Peripheral blood B cell depletion after rituximab and complete response in lupus nephritis. *Clin J Am Soc Nephrol*. 2018;13:1502-9.
- Merrill JT, Furie R, Werth VP et al. Anifrolumab effects on rash and arthritis: impact of the type I interferon gene signature in the phase IIb MUSE study in patients with systemic lupus erythematosus. *Lupus Sci Med*. 2018 Nov 26;5(1):e000284. doi: 10.1136/lupus-2018-000284. PMID: 30588322; PMCID: PMC6280909.
- Furie RA, Morand EF, Bruce IN et al. Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial. *Lancet Rheumatol*. 2019;1(4):E208.
- Morand EF, Furie R, Tanaka Y et al. Trial of Anifrolumab in Active Systemic Lupus Erythematosus. *N Engl J Med*. 2020;382(3):211. Epub 2019 Dec 18.
- Tummala R, Abreu G, Pineda L et al. Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trials. *Lupus Sci Med*. 2021 Feb;8(1):e000464. doi: 10.1136/lupus-2020-000464. PMID: 33597205; PMCID: PMC7893670.
- Drosos GC, Vedder D, Houben E et al. EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome. *Ann Rheum Dis*. 2022 Jun;81(6):768-779. doi: 10.1136/annrheumdis-2021-221733. Epub 2022 Feb 2. PMID: 35110331.
- Furer V, Rondaan C, Heijstek MW et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. *Ann Rheum Dis*. 2020 Jan;79(1):39-52. doi: 10.1136/annrheumdis-2019-215882. Epub 2019 Aug 14. PMID: 31413005.